APP and infection: But the discovery that HIV-1 evades restriction by APP by increasing its amyloidogenic processing offers both an explanation for why infection increases toxic amyloid production and a therapeutic opportunity to simultaneously block amyloid production and harness APP’s antiviral activity through the use of γ-secretase inhibitors16.